All Grants

Call for Cancer Projects: Repurposing of Drugs - Breakthrough in Cancer Treatment

Funding Cancer Projects

Reliable Cancer Therapies (RCT) announces € 300 000 for projects repurposing existing drugs for cancer treatment.  The drugs must have been developed and approved for other indication(s). Relevant clinical trial endpoints (cancer survival & tumor response) should be the primary research assessments.

RCT also promotes collaborative research projects between researchers at different universities and/or organisations.

About the Call for Applications

• Medical Degree required for Principal Investigator (PI) or co-PI

• 1 application per PI

• Resubmission is allowed (please indicate the reason for previous decline)

• Set up of proposal:

◦ Application form: maximum 2 pages

◦ in appendix 1: biography & references of the PI and co-PI

◦ in appendix 2: overview of the budget (including salaries, supplies, equipment, patient care costs, and other expenses).

• If your cancer project is selected in the first round, detailled information will be requested for consideration of the final award selections.

• Approved proposals will be supported with a maximum of  € 300 000 for 3 years.

Reliable Cancer Therapies (RCT) is a non-profit organization based in Switzerland that provides research-based information on cancer therapies and selectively funds the development of promising therapies.

RCT investigates information on cancer therapies for evidence to then inform the public about evidence-based cancer treatment choices. We help cancer patients and caregivers to structure and absorb the complex nature of cancer information for their decision-making on registered complementary or alternative therapies.

RCT is continuously looking for cancer therapies that have never been thoroughly examined and consider financing cancer treatments that can be deemed promising based on measurable results.

Application Deadline

Application deadline is June 28, 2013 at 8am GMT. Incomplete or late applications will not be considered.

Please submit applications to Ann-Christine Moenaert (info@reliablecancertherapies.com)

RCT will review the applications internally with the support from our appropriate external experts by August 14, 2013. If the project is selected in the first round, more detailled information will be requested by September 13, 2013.  Final decisions will be made on October 4, 2013.

Contacts at RCT

Please direct any technical questions to Ann-Christine Moenaert (info@reliablecancertherapies.com)

Please contact Gauthier Bouche, MD (info@reliablecancertherapies.com) for any clinical or scientific questions.

Call for Applications for 2014: Center of Excellence for Comparative Effectiveness Research

Application deadline: September 15, 2013

Program start date January 1, 2014

It is an exciting time to work in the health care field, as Comparative Effectiveness Research (CER) has become a
national priority. Information, options, and outcomes are the facets of CER—research that has gained widespread
attention while medical innovation continues to generate more tests, treatments, and alternative therapies for
patients worldwide. Developing a skilled CER workforce is essential for effectively comparing the benefits and risks
of existing treatments and translating those findings into optimal care. Universities and medical schools have the
potential to shape this emerging field as they train the next generation of CER specialists. The PhRMA Foundation
is showing its support of CER education by awarding annual grants to institutions that will develop comprehensive,
degree-granting programs in CER. Each grant will be for $250,000 and distributed over a three-year period.

The purpose of this program is to provide funding to a U.S. educational institution in order for it to develop or
expand a degree-granting program in comparative effectiveness research (CER).

Eligibility

Organizations/institutions eligible to apply include those academic degree granting programs with an existing NIH
or AHRQ-funded CER research or training program and the capacity to develop a degree-granting program in CER
using existing tenure track professors.

Applications are available online at www.phrmafoundation.org and the application submission deadline is September 15, 2013. This award will begin on January 1, 2014.

ISCTR-American College of Cardiology Foundation Cardiovascular Translational Research Scholarship

sponsored by Dignity Health, St. John's Hospital

The purpose of the program is to recognize and provide financial support for research efforts by outstanding cardiovascular scholars. This scholarship is to encourage junior faculty in the early phases of their careers in the field of cardiology. The program is intended for a physician with a strong interest in developing a career in cardiovascular translational research.

One year of previous interventional cardiology training is required. The duration of the program is one year. The awardee will develop skills and expertise in translating basic biological and device concepts into clinical application.

Goal: The overall goal of the program is to provide the clinical scientist (a physician) with the necessary scientific background that does not exist in today's curriculum. The program will enable the awardee to expedite scientific discovery to clinical application, ultimately benefitting the patient and society by providing science earlier and decreasing the developmental costs related to new devices and/or novel biologic therapies.

The program will cover the topics of:

• Basic science

• Preclinical science

• Clinical science and trial design

• Regulatory pathways (FDA) for IND (investigational new drug application) and IDE (investigational new device exemption)

The emphasis will be on biologics (stem cell therapy and genomics) and cardiovascular device development.

Objectives: The fellow will:

• Develop the skills and knowledge to take a scientific concept to the bedside

• Gain substantial knowledge about the steps in cardiovascular translational research

• Understand product development related to devices or biologics 

• Learn about toxicology studies required on small and large animal models that serve for IND or IDE application 

• Understand the statistical design and analysis required for toxicology studies, and phase I, II, and III clinical trials 

• Learn about the regulatory pathways for and how to prepare an IND (Investigational Drug Application) and an IDE (Investigational Device Exemption)

• Understand fundraising, NIH grant application process, opportunities in the venture capital arena, and developing and maintaining relationships with industry

Eligibility: Applicants eligible for the award are those who:

• Have completed one year of previous interventional cardiology. 

• Are members or are eligible to become a member of the ACC and ISCTR

• Will spend the duration of the Scholarship at an institution that has the ability to perform translational research (conducts both preclinical and clinical research) and can administer the curriculum found here:

http://www.cardiosource.org/~/media/Files/ACC/Membership/awards/ISCTR%20Curriculum.ashx

The Award: The award will offer $60,000 of salary support to begin July 1, 2014 and run through June 30, 2015.

Funding Source: The ACCF is grateful to Dignity Health St. John’s Hospital for their financial support for this award.

Nomination Procedure: Criteria for selection includes qualifications, background, interests, and commitment of the applicant.

How to Apply: The submission site for applications will open this summer. Please stay tuned for more information.

Deadline: September 23, 2013

For more information: Email Julia Berman or call 800-253-4636, ext. 6648.

American College of Cardiology Foundation/Merck Research Fellowships in Cardiovascular Disease

Four one-year fellowships will be awarded to support research in adult cardiology. Preference is given to individuals who have had no more than two years of prior full-time experience either in clinical or basic research. Recipients will be expected to pursue a full-time project in clinical research during their year of supported training.

Research Focus: In selecting applications, proposals addressing CVD and Cardiometabolic disorders are encouraged. Included are proposals that address pathophysiology, molecular genetics, metabolic abnormalities leading to cardiovascular disease, hypertension, heart failure, hyperlipidemia, inflammatory mechanisms and new pathways for drug discovery. Proposals focusing on clinically relevant outcomes as a result of the metabolic syndrome, diabetes or obesity are also encouraged. Outcomes studies should focus on clinical/and or systems of care (e.g., quality improvement) interventions, and use outcomes measures of importance to both patients and society, including mortality, significant morbidity or quality of life changes, or economic effects.

Preference for one award will be given to applicants focusing on disparities of care.  Despite increased attention to health disparities at the national, state and community levels, relatively little progress has been made in achieving the vision of eliminating racial and ethnic health disparities.  Since the rates of cardiovascular mortality in the United States are significantly higher for these patients and this is, in fact, the leading cause of death in this demographic, innovative approaches to eliminating these disparities are critical.  In an effort to encourage and support research in this area, proposals will be encouraged that focus on gender, race, geographic, and economic inequalities in cardiovascular care.

Eligibility: Anyone currently in an adult cardiology fellowship training program recognized by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association and who has the recommendation and agreement of his/her training program director and institution.

Selection: Judging will be by the ACCF/Research Fellowship Awards Committee. Criteria for selection will include:

• Scientific quality of the project;

• Relevance to the research focus as described above;

• Qualifications and commitment of the applicant; and

• The quality of the training environment.

Successful applicants may pursue this protected year of research either within or following their three years of required training. Preference will be given to individuals who:

• Will pursue clinical research training and experience directly involving patients or human subjects.

• Have had no more than two years of prior full-time research experience either in clinical or basic research.

• Will not hold another major external fellowship or salary award, (e.g., from the National Institutes of Health or the American Heart Association) during the ACCF/Merck funded year.

The Award: Four fellowships in the amount of $70,000 each, to be used for salary support, for one year of research to begin July 1, 2014 and run through June 30, 2015.

Funding Source: The ACCF is grateful to the Merck Company Foundation for their continued financial support for these awards.

Deadline: September 23, 2013

For more information: Email Julia Berman or call 800-253-4636, ext. 6648.

American College of Cardiology Foundation/William F. Keating, Esq. Endowment Career Development Award

The purpose of the award is to recognize and provide financial support for research efforts by outstanding your cardiovascular scholars. This award is to encourage junior faculty in the early phases of their careers in the field of cardiology. The award will provide one junior faculty member with a year of research support. Preference will be given to applications focusing on hypertension and/or peripheral vascular disease.

Eligibility: Applicants eligible for the award are those who:

1. Will hold rank of instructor or assistant professor at the time of the initiation of the award and have completed adult, pediatric, surgical cardiology fellowship training in a program approved by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association;

2. Are members or are eligible to become a member of the American College of Cardiology (ACC);

3. Are no more than five years out of training;

4. Have the recommendation and agreement of their division chiefs and their chiefs' assurance that the awards' support will provide protected time for the applicants to pursue their research programs; and

5. Have an agreement with their institutions that the full amount of the award will be designated for the salary support.
The Award: The award will offer $70,000 salary support for one year of research to begin July 1, 2014 and run through June 30, 2015.

Funding Source: The ACC is grateful to the William F. Keating Endowment Fund for supporting this award.

Nomination Procedure: Criteria for selection includes scientific quality of the project, qualifications and commitment of the applicant, and support of the environment to foster the proposed project and applicant's success. Preference will be given to applications focusing on hypertension and/or peripheral vascular disease

Application Deadline: September 23, 2013

For more information: Email Julia Berman or call 800-253-4636, ext. 6648.

American College of Cardiology Foundation Young Investigator Awards Competition

The Young Investigator Awards competition encourages and recognizes young scientific investigators of promise, upon whom progress in the field of cardiology is dependent. A manuscript and abstract summarizing any problem that relates to cardiovascular disease whether it be in etiology, pathophysiology, diagnosis, or therapy.

Award Categories include the following:

1. ACCF/Herman K. Gold Young Investigator Awards in Molecular and Cellular Cardiology

2. Physiology, Pharmacology and Pathology

3. Clinical Investigations, Congenital Heart Disease and Cardiac Surgery

4.Cardiovascular Health Outcomes and Population Genetics

*Doctorate level nurses, physician assistants and clinical pharmacists in research are strongly encouraged to apply in this category

Eligibility: Physicians, scientists, medical students, and other healthcare providers currently in residency or fellowship programs, or are no more than three years out of training. PhD, PharmD or DNP candidates who are no more than three years out of training may also apply.    

Note: Candidates will be eligible for this award up to four years after completion of training if more than three months of family or sick leave was taken during training or in the first three years after completion of training.

The Award: The first place winner for each category receives $2,000, second place winners receive $1,000; three honorable mentions in each category receive $500. Travel, hotel and meals up to $1,500 will be reimbursed for all 20 finalists to attend the YIA Competition at ACC.14 in Washington, DC.

Funding Source: Support for the ACCF/Herman K. Gold Young Investigator Awards in Molecular and Cellular Cardiology is provided by a grant from CV Path Institute and the family of Herman K. Gold.

Deadline: October 11, 2013

For more information: Email Kristin Robertson or call 800-253-4636, ext. 6390.

2014 Family Medicine Cares Resident Service Award

This service award requires that the resident identify an unmet health care need in his/her community. The resident will then design an innovative service project at a free health clinic (or similar health care facility) to address that unmet health care need and will implement the project for 12 months. The project should enhance the services offered by the free health clinic and have relevance to the patient population being served.

In designing the project, emphasis should be placed on activities that will have an enduring benefit to the patients and the community after the 12-month project period. Projects that can be continued or replicated by other family medicine residents in the future are also encouraged.

Note: It may be helpful to obtain input from the clinic’s staff when designing the project.

Eligibility

All first-year and second-year family medicine residents who are members of the American Academy of Family Physicians (AAFP) are eligible to apply. All applicants must still be residents when the project period ends.

Project Period

The project period will be May 1, 2014 to April 30, 2015.

Award

One award will be provided annually. The award will total $16,500 and contain the following elements:

• A $10,000 award will be provided to the resident whose service project is selected for funding. This funding is to be used by the resident only for costs directly related to the project. These may include: medical supplies (e.g., diabetes testing), equipment rental or purchase, software purchase or lease, patient education materials, communication expenses (e.g., postage, printing, office supplies), patient incentives/reimbursement, mileage/transportation (e.g., resident mileage), patient reimbursement, personnel not employed by free clinic or health care facility (e.g., patient educators, substance abuse or peer counselors).

• $5,000 award will be provided to the free clinic (or similar health care facility) where the service project is implemented. 

• $1,000 travel award will be provided to the resident to attend the 2015 National Conference (NC) of Family Medicine Residents and Medical Students. The resident will present the results of the project at this conference. 

• $500 stipend will be given to the residency program to celebrate and recognize the resident who wins the Family Medicine Cares Resident Service Award.

Required of Resident

The resident is required to submit the following reports:

• An interim financial report and progress report that highlights the service project activities and progress is required by November 1, 2014.

• A final financial report and final project summary detailing the implemented service project and its outcomes must be submitted by June 1, 2015.

• The resident will attend the 2015 National Conference (NC) of Medicine Residents and Medical Students to give a presentation on his/her project. Note: Registration fees for the NC will be waived for speakers.

Required Report from Clinic

The free clinic (or similar health care facility) is required to submit documentation six months after the resident’s project begins describing how the $5,000 award to the clinic is being utilized.

Letters of Recommendation/Support

Three letters are required to be submitted with the application:

• One letter of recommendation from the resident’s residency director 

• One letter of support from the director of the free clinic (or other health care facility) 

• One letter from the mentor (clinic director or other physician) agreeing to assist with the project should the award be granted

Deadline

The deadline for the application is February 1, 2014.

Award Announcement

The winner of the Resident Service Award will be announced by April 1, 2014.

Dissemination of Award

The $10,000 award for the resident will be distributed in three payments:

• $6,000 will be provided at the start of the project

• $2,000 will be provided after receipt of the interim reports

• $2,000 will be provided after receipt of the final reports

The $5,000 award for the free clinic will be distributed in two payments:

• $2,500 will be provided at the start of the project

• $2,500 will be provided after receipt of the clinic’s report six months after the project begins

The $500 stipend for the residency will be distributed when the award is announced.

How to Submit Your Application

All materials should be emailed and the original mailed (postmarked) no later than February 1, 2014 to: Susie Morantz, 11400 Tomahawk Creek Parkway, Suite 440, Leawood, KS 66211.

Questions

If you have any questions please feel free to email or call Susie Morantz at 800-274-2237, ext. 4470.

ALS Therapy Alliance Grants Program

Thank you for your interest in submitting a proposal for grant funding to the ALS Therapy Alliance (ATA). Our organization traditionally awards grants from one to three years in term ranging from $100,000 to $1 million in funding to both non- and for-profit companies. National and international companies are eligible to apply.

The following outline will help you prepare the information needed for our next funding review, which happens twice a year in April and November.

Please note grant submission deadlines and number of copies requested in order to ensure timely processing of your application. The ALS Therapy Alliance does not cover indirect costs.

If you have questions about the submission process or this application, please contact Ray Bisson, Grants Manager at (603) 664-5005 or ray@alstherapyalliance.org, or visit our FAQ page.

http://alstherapyalliance.org/index.php/research/grant-submission-process/faqs.html

What to include with your grant proposal

ATA grant applications should follow the following format and adhere strictly to the maximum page limits (using only 11 point font or greater):

■ Abstract (1 page)

■ Background and Significance (2 pages)

■ Preliminary Data (2 pages)

■ Experimental Plan (3 pages)

■ References (no limit)

■ Budget

■ Budget Justification

■ NIH Biosketch (including present and pending support, 4 pages maximum) for PI's, post-docs and others involved in the project (excluding laboratory technicians)

■ Letters of collaboration and support

Grant proposal submission deadlines

To have your grant proposal reviewed at our April meeting, please submit by March 15th. To have your grant proposal reviewed at our November meeting, please submit by October 15th.

Where to send your grant proposal

Please email your proposal in PDF format to ray@alstherapyalliance.org.

ALS Therapy Alliance Grants Program

Thank you for your interest in submitting a proposal for grant funding to the ALS Therapy Alliance (ATA). Our organization traditionally awards grants from one to three years in term ranging from $100,000 to $1 million in funding to both non- and for-profit companies. National and international companies are eligible to apply.

The following outline will help you prepare the information needed for our next funding review, which happens twice a year in April and November.

Please note grant submission deadlines and number of copies requested in order to ensure timely processing of your application. The ALS Therapy Alliance does not cover indirect costs.

If you have questions about the submission process or this application, please contact Ray Bisson, Grants Manager at (603) 664-5005 or ray@alstherapyalliance.org, or visit our FAQ page.

http://alstherapyalliance.org/index.php/research/grant-submission-process/faqs.html

What to include with your grant proposal

ATA grant applications should follow the following format and adhere strictly to the maximum page limits (using only 11 point font or greater):

■ Abstract (1 page)

■ Background and Significance (2 pages)

■ Preliminary Data (2 pages)

■ Experimental Plan (3 pages)

■ References (no limit)

■ Budget

■ Budget Justification

■ NIH Biosketch (including present and pending support, 4 pages maximum) for PI's, post-docs and others involved in the project (excluding laboratory technicians)

■ Letters of collaboration and support

Grant proposal submission deadlines

To have your grant proposal reviewed at our April meeting, please submit by March 15th. To have your grant proposal reviewed at our November meeting, please submit by October 15th.

Where to send your grant proposal

Please email your proposal in PDF format to ray@alstherapyalliance.org.

Call for Applications: Meso Foundation Research Grants

The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:

·  Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;

·  Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and

·  Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.

The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.

Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.

Encouraged projects include, but are not limited to, investigations of:

1. Strategies for early detection of new or progressive disease;

2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;

3. Therapeutic intervention, including but not limited to;

a. Immune Response Targeted Therapy

b. Novel chemotherapeutic compounds

c. Novel radiation or surgical techniques

4. Determination of clinical/molecular determinants for prognosis

Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.

Applications will be evaluated on the following criteria:

Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?

Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.